DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease Met Primary and Secondary Endpoints
Horizon Pharma plc today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent of teprotumumab patients compared to 9.5 percent of placebo patients achieved the primary endpoint of a 2 mm or more reduction in proptosis (p<0.001). Proptosis is the main cause of morbidity in TED. All secondary endpoints were also met and the safety profile was consistent with the Phase 2 study of teprotumumab in TED.
Horizon expects to submit a Biologics License Application to the U.S. Food and Drug Administration (FDA) in mid-2019. Teprotumumab has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. Detailed Phase 3 data will be submitted for publication in a peer-reviewed journal and presented at a medical congress later this year.


Related Content
-
People & PlacesScheie Eye Institute – Thyroid Eye Disease ProgramScheie’s Thyroid Eye Disease Program o...
-
News & MeetingsTeprotumumab Significantly Improves Proptosis in Thyroid eye DiseasePatients with thyroid eye disease treate...
-
Evidence & EducationEnfermedad De Graves en Bebés Recién Nacido¿Cuáles Son las Causas de La Enfermeda...
-
People & PlacesVictor Maurice Elner, MD, PhDVictor Maurice Elner is a Professor of o...
-
Evidence & EducationComparison of Two Different Regimens of Intravenous Methylprednisolone for Patients With Moderate to Severe and Acti...The intravenous methylprednisolone (iv M...
-
Evidence & EducationDeath by Suicide in Graves’ Disease and Graves’ Orbitopathy: A Nationwide Danish Register StudyBackground: Graves' disease (GD) is ass...
-
Evidence & EducationThyroid Eye Disease – What to ExpectHow does the disease progress? There ar...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.